GlaxoSmithKline Granted Europe Marketing Authorisation For Relvar Ellipta

Mon, 18th Nov 2013 13:31

LONDON (Alliance News) - GlaxoSmithKline PLC Monday said that the European Commission has granted marketing authorisation for asthma and chronic pulmonary disease drug Relvar Ellipta, which is now licenced across 31 European countries.

The pharmaceuticals giant said that under the terms of a 2002 collaboration, Theravance Inc. is obligated to make a milestone payment to Glaxo of USD15 million following the marketing authorisation.

Glaxo shares were up 0.4% to 1,621.5 pence Monday.

By Tom McIvor; tommcivor@alliancenews.com; @TomMcIvor1

Related Shares

More News

24 May 2024 15:19

London close: Stocks mixed after disappointing retail sales data

(Sharecast News) - London stocks closed with mixed results on Friday, influenced by earlier declines in the US and Asian markets, as investors reacted...

24 May 2024 08:55

LONDON MARKET OPEN: FTSE 100 falls; retail sales plunge in April

(Alliance News) - Stock prices in London opened lower on Friday, with sentiment hurt across the globe.

24 May 2024 08:36

TOP NEWS: GSK celebrates Illinois jury verdict in Valadez case

(Alliance News) - GSK PLC on Friday welcomed the jury verdict in the Valadez case in Illinois state court, which found in GSK's favour in the first Za...

24 May 2024 07:52

LONDON BRIEFING: UK retail sales fall amid wet April; Co-Op Bank deal

(Alliance News) - Stocks are called to open lower on Friday, following New York lower, as hopes of interest rate cuts have come into question.

24 May 2024 07:30

Jury rules in favour of GSK in Zantac trial

(Sharecast News) - A court in Illinois has ruled in favour of GSK in the first Zantac case to go to trial, the UK drugs giant confirmed on Friday.